Enables secure real-time document review, co-authoring, and redaction in order to shorten the document review process by up to 65%.

ProPharma has deep expertise across all signal detection and management activities, including validation, prioritization, and assessment using data from a wide range of sources that are relevant for signal detection for the individual product(s). We are also fully trained and experienced in the EudraVigilance Data Analysis System (EVDAS) functionality and can support MAHs to comply with their obligations for signal detection and management. We leverage our robust knowledge to select the most efficient and effective method(s) for each product that is compliant with legislative requirements.

What can 22,000 people with an AI-mindset accomplish?

Speed without shortcuts

AI in clinical development at Parexel enables our teams to surface predictive insights at every stage, reducing protocol risk, study delays, and costly trial amendments.

Parexel's approach to AI in clinical development is built on the Precision Pathway, a strategic operating model that embeds AI across the full trial lifecycle. AI empowers our teams at critical decision points to:

1. Simplify complex tasks to accelerate timelines: AI capabilities are delivering up to 50% cycle time reductions in IND submission generation.
2. Apply insights with agility to enable better decision-making
3. Enhance data handling to drive first-time quality through content generation and workflow automation

With ParexelAI™, you're not just optimizing your current development timeline, you're unlocking the ability to run more programs simultaneously across our global network and compress critical timelines. In a landscape where speed to market directly impacts patient outcomes, ParexelAI empowers you to innovate and make a meaningful difference in patients' lives.

Computer System Validation to cover all your GMP, GLP, GCP, and QA/QC software applications. CompliancePath currently has 30+ active projects globally supporting clients in CSV/CSA compliance.

Navigating drug safety in the era of innovation-driven medicine

The focus on drug safety and pharmacovigilance has never been more intense. Patient safety remains paramount throughout a product's lifecycle, even as sponsors and marketing authorization holders (MAHs) face increasing complexity in managing safety data. This complexity stems from huge volumes of data generated from scores of diverse sources, much of it rapidly expanding unstructured data. Innovation-driven medicine is a key factor. These dynamics are reshaping the landscape of drug safety, presenting both challenges and opportunities for innovation in pharmacovigilance practices.

Developing a therapy for a rare or ultra-rare disease is life-changing work with unique challenges. Examine how natural history data is being used to inform the clinical development process.

Elevate Your Clinical Research Data Collection